Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01951950 · ClinicalTrials.gov registry record · Phase 1
Nicardipine vs Esmolol Craniotomy Emergence
A Phase 1 study of Brain Tumors, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT01951950 is a Phase 1 study of Brain Tumors that has completed, run by Northwestern University. The registered enrollment target is 40 participants, below the 6,339-participant average among 10 other Brain Tumors trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01951950, a Phase 1 study of Brain Tumors, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Emergence hypertension is a common occurrence in patients emerging from general anesthesia. This elevation of arterial pressure is particularly concerning in patients undergoing craniotomy due to increased risk of morbidity and mortality in patients with altered intracranial elastance. Thus, identifying better methods to attenuate the hemodynamic changes associated with emergence from anesthesia can improve patient safety, especially in the neurosurgical patient. Study Hypothesis: Nicardipine is more effective than esmolol as a sole agent in maintaining blood pressure within goal range in the setting of emergence hypertension after craniotomy.
Conditions Studied
Interventions
- DRUG Nicardipine
- DRUG Esmolol
Study Locations (1)
Illinois
- Northwestern Memorial Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01951950
The ClinicalTrials.gov registry entry for NCT01951950 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,339-participant average among 10 other Brain Tumors trials with a reported enrollment target (99% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Tumors appearing as the primary indexed condition, and to 2 interventions - of which Nicardipine is the first listed.
NCT01951950 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT01951950 about?
NCT01951950 is a clinical study titled "Nicardipine vs Esmolol Craniotomy Emergence". Emergence hypertension is a common occurrence in patients emerging from general anesthesia. This elevation of arterial pressure is particularly concerning in patients undergoing craniotomy due to increased risk of morbidity and mortality in patients with altered intracranial elastance. Thus, identif...
What is the current status of trial NCT01951950?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2013-09. Estimated completion is 2014-05.
What conditions does trial NCT01951950 study?
This clinical trial studies the following conditions: Brain Tumors.
What interventions are being tested in trial NCT01951950?
The interventions under investigation include: Nicardipine (DRUG), Esmolol (DRUG).
Who is sponsoring clinical trial NCT01951950?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01951950 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ALA-induced PpIX Fluorescence During Brain Tumor Resection
ACTIVE NOT RECRUITING · Phase 1
-
[F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors
COMPLETED · Phase 1
-
Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
COMPLETED · Phase 1
-
Florida Center for Brain Tumor Research
RECRUITING
-
Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies
ACTIVE NOT RECRUITING
-
Blood Flow MRI for Monitoring Brain Tumors
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.